Nav: Home

Study of patients with melanoma finds most have few moles

March 02, 2016

Most patients with melanoma had few moles and no atypical moles, and in patients younger than 60, thick melanomas were more commonly found in those with fewer moles but more atypical moles, according to an article published online by JAMA Dermatology.

Studies have suggested that the number of total moles and atypical moles is associated with the risk of melanoma. Yet the relationship of those mole patterns with tumor thickness and cancer prognosis is complex.

Alan C. Geller, M.P.H., R.N., of the Harvard T.H. Chan School of Public Health, Boston, and coauthors looked at the association between age and total moles and atypical moles and whether there was a relationship between total moles or atypical moles and tumor thickness, a very important prognostic indicator for melanoma.

The study included 566 patients with melanoma and most of them (66.4 percent or 376) had zero to 20 total moles, while 73.3 percent (415 patients) had no atypical moles.

In patients younger than 60, having more than 50 total moles was associated with reduced risk for thick melanoma, while having more than five atypical moles compared with no atypical moles was associated with thicker melanoma, according to the results.

"Several public health messages emerge from our study, including that melanomas are more commonly diagnosed in individuals with fewer nevi compared with those with a high mole count. Therefore, physicians and patients should not rely on the total nevus count as a sole reason to perform skin examinations or to determine a patient's at-risk status," the study concludes.
-end-
(JAMA Dermatology. Published online March 2, 2016. doi:10.1001/jamadermatol.2016.0027. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: This study was supported by Merck and Co., Inc. The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact corresponding study author Alan C. Geller, M.P.H., R.N., call Todd Datz at 617-432-8413 or email tdatz@hsph.harvard.edu

To place an electronic embedded link in your story: Links will be live at the embargo time: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2016.0027

The JAMA Network Journals

Related Melanoma Articles:

Immunity against melanoma is only skin deep
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
Researchers document how melanoma tumors form
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
NIH study reveals how melanoma spreads
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
Melanoma research breakthrough gives hope to treatment
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
Study examines melanoma incidence, death
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
Research providing promising new treatments for melanoma
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
A protein that defines the melanoma blueprint
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Nanotechnology supports treatment of malignant melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Detecting melanoma early, without a biopsy
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.

Related Melanoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".